0.91
+11.55%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Organogenesis Holdings
From its filings with the US Securities and Exchange Commission
Organogenesis Holdings is based in Canton, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ORGO. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $564.2m and net income of $37.0m. At that date it held total assets of $598.7m and shareholders' equity of $300.1m. By business, Product [Member] brought in 99.8% of revenue, followed by Grant [Member] at 0.2%.
Organogenesis is a leading regenerative medicine company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care and surgical and sports medicine markets.
Our mission is advancing healing and recovery beyond expectations. Several of our existing and pipeline products in our portfolio have Premarket Application (“PMA”) approval, or 510(k) clearance from the United States Food and Drug Administration (“FDA”). Our solutions address large and growing markets driven by aging demographics and increases in comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease. We offer our differentiated products and in-house customer support to a wide range of health care customers including hospitals, wound care centers, government facilities, ambulatory surgery centers (“ASCs”) and physician offices.
In the Advanced Wound Care market, we focus on the development and commercialization of products for the treatment of chronic and acute wounds. We have a portfolio of regenerative medicine products capable of supporting patients from early in the wound healing process through wound closure.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Dec 2016
- Employees
- 854
- Website
- investors.organogenesis.com ↗
- Head office
- 85 DAN ROAD, CANTON, MA, 02021
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Mr. Gary GillheeneyChairman of the Board, President, Chief Executive Officer, since 2014$7.0m
- Mr. David FranciscoChief Financial Officer$2.0m
- Mr. Patrick BilboChief Operating Officer$2.3m
- Mrs. Lori FreedmanChief Administrative and Legal Officer$2.0m
- Mr. Robert CavorsiVice President - Strategy
- Mr. Antonio MontecalvoVice President - Health Policy
- Mr. Brian GrowChief Commercial Officer$2.1m
- Mr. Arthur LeibowitzLead Independent Director$317,500
- Mr. Robert AdesDirector
- Mr. Glenn NussdorfDirector
- Dr. Michael DriscollIndependent Director$237,500
- Ms. Prathyusha DuraibabuIndependent Director$250,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 46
- Environment
- 44
- Social
- 82
- Governance
- 10
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Organogenesis Holdings Inc boasts an advanced technology platform that enables the development and production of cutting-edge products in the field of regenerative medicine. The company offers a diverse portfolio, including innovative therapies for wound healing and surgical applications, providing a competitive advantage in the market.
- With years of experience and a solid reputation, Organogenesis Holdings Inc has established itself as a prominent player in the regenerative medicine industry. The company's strong market position allows it to leverage its brand recognition, expand its customer base, and maintain a steady revenue stream.
Weaknesses
- Organogenesis Holdings Inc relies on external suppliers for certain critical components of its products. This dependence introduces the risk of supply chain disruptions, potential quality control issues, and increased vulnerability to price fluctuations. Implementing strategies to diversify suppliers and ensure stable procurement processes are crucial in mitigating this weakness.
- Despite its success, Organogenesis Holdings Inc has a relatively limited global presence compared to some of its competitors. Expanding its market reach to untapped regions and establishing strategic partnerships or distribution networks can help overcome this weakness and increase its market share.
Opportunities
- The increasing awareness and acceptance of regenerative medicine present a significant growth opportunity for Organogenesis Holdings Inc. With the potential to address unmet medical needs, the company can capitalize on the growing demand by continually innovating and developing new and improved products.
- Entering emerging markets where the adoption of regenerative medicine is still in its early stages can offer Organogenesis Holdings Inc substantial opportunities for expansion. By understanding local regulations, tailoring marketing strategies, and establishing strong relationships with local healthcare providers, the company can tap into new customer bases and drive long-term growth.
Threats
- The regenerative medicine industry is subject to strict regulatory oversight, which can pose challenges for Organogenesis Holdings Inc. Changes in regulations or delays in obtaining necessary approvals for new products may impact the company's speed to market and hinder its ability to adapt to evolving industry requirements.
- The market for regenerative medicine is highly competitive, with numerous established players and emerging startups vying for market share. Organogenesis Holdings Inc faces the risk of competitors launching similar or superior products, potentially leading to price pressures and loss of market position. Staying ahead through continuous innovation, effective marketing strategies, and fostering key partnerships will be crucial in mitigating this threat.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.